by David Cassak and Stephen Levin
Uneasy lies the head that wears the crown, said Shakespeare. In business, market leadership is an enviable position—until things start going wrong. Then, it almost becomes a burden; market leaders...
Zimmer Redux
Six months after a significant management change, Zimmer officials claim the orthopedics leader is back on track. But in today's environment, can even a successful orthopedics company please its drug-company parent?
More from Business Strategy
More from In Vivo
• By
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
• By
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
• By
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.